TELVELZO Trademark
Trademark Overview
On Monday, February 2, 2026, a trademark application was filed for TELVELZO with the United States Patent and Trademark Office. The USPTO has given the TELVELZO trademark a serial number of 99628002. The federal status of this trademark filing is APPROVED FOR PUBLICATION as of Saturday, May 30, 2026. This trademark is owned by Elixirgen Therapeutics, Inc.. The TELVELZO trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells
General Information
| Serial Number | 99628002 |
| Word Mark | TELVELZO |
| Filing Date | Monday, February 2, 2026 |
| Status | 680 - APPROVED FOR PUBLICATION |
| Status Date | Saturday, May 30, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Goods and Services | Pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders, and blood-based diseases; pharmaceutical preparations for cell and gene therapy for the treatment of blood cells, blood disorders and blood-based diseases and to be infused to a human subject; pharmaceutical preparations for cell and gene therapy for the treatment of bone marrow; pharmaceutical preparations containing cells treated with vectors encoding proteins for elongating telomeres in blood cells; pharmaceutical preparations containing blood cells treated with vectors encoding ZSCAN4 proteins for elongating telomeres in the blood cells; pharmaceutical preparations containing blood cells treated with Sendai virus vectors encoding proteins for elongating telomeres in the blood cells |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, February 2, 2026 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Elixirgen Therapeutics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Baltimore, MD 21205
US |
Trademark Events
| Event Date | Event Description |
| Monday, February 2, 2026 | NEW APPLICATION ENTERED |
| Monday, February 2, 2026 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, February 2, 2026 | APPLICATION FILING RECEIPT MAILED |
| Friday, May 29, 2026 | ASSIGNED TO EXAMINER |
| Saturday, May 30, 2026 | APPROVED FOR PUB - PRINCIPAL REGISTER |
